Loading…

The Use of TNF[alpha] Inhibitors in Treating Pediatric Skin Disorders

Tumor necrosis factor alpha (TNF) inhibitors have had a significant impact in medicine since the approval of the first drug of its class by the US FDA in 1998. New clinical data and indications have emerged for TNF inhibitors in recent years. Currently, four TNF inhibitors have been approved by the...

Full description

Saved in:
Bibliographic Details
Published in:Paediatric drugs 2020-06, Vol.22 (3), p.311
Main Authors: Nguyen, Quoc-Bao D, Starling, Caroline T, Hebert, Adelaide A
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 3
container_start_page 311
container_title Paediatric drugs
container_volume 22
creator Nguyen, Quoc-Bao D
Starling, Caroline T
Hebert, Adelaide A
description Tumor necrosis factor alpha (TNF) inhibitors have had a significant impact in medicine since the approval of the first drug of its class by the US FDA in 1998. New clinical data and indications have emerged for TNF inhibitors in recent years. Currently, four TNF inhibitors have been approved by the US FDA for dermatology, two of which include US FDA-approved pediatric use. In particular, growing evidence supports the use of etanercept and adalimumab as attractive therapies for pediatric psoriasis. Data for use of etanercept in treating toxic epidermal necrolysis and either etanercept or infliximab for Kawasaki disease is expanding. In addition, there have been clinical reports on the use of TNF inhibitors to treat a variety of other pediatric dermatologic conditions. To help clinicians keep pace with the new data provided by many pediatric dermatology studies involving TNF inhibitors, this review provides an overview of the use of TNF inhibitors in the treatment of pediatric plaque psoriasis, hidradenitis suppurativa, atopic dermatitis, pyoderma gangrenosum, toxic epidermal necrolysis, and Kawasaki disease. For TNF inhibitors with little data in the pediatric population, data on adult use is discussed. Furthermore, the review summarizes available clinical data on efficacy, safety, and tolerability of agents currently available.
doi_str_mv 10.1007/s40272-020-00394-3
format article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A714588622</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A714588622</galeid><sourcerecordid>A714588622</sourcerecordid><originalsourceid>FETCH-LOGICAL-g672-42934943428404bc2e831657fd2251c30909fa77ef4704a2e36db1b3d101ea543</originalsourceid><addsrcrecordid>eNptjsFLwzAYxXNQcE7_AU8Bz5lfkq9Nehxzc4OhgvUkMtL0SxvdWmn6_2NBDx7kHR48fu_xGLuRsJAA5i4hKKMEKBAAukChz9hMSoMis8ZesMuUPgCk0bmasXXZEn9NxPvAy8fNmzt-te6d77o2VnHsh8Rjx8uB3Bi7hj9THd04RM9fPqf8PqZ-qGlIV-w8uGOi61-fs3KzLldbsX962K2We9Hk0yNUhcYCNSqLgJVXZLXMMxNqpTLpNRRQBGcMBTSATpHO60pWupYgyWWo5-z2Z7ZxRzrELvTj4PwpJn9YGomZtblSE7X4h5pU0yn6vqMQp_xP4RsU4FiZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The Use of TNF[alpha] Inhibitors in Treating Pediatric Skin Disorders</title><source>Nexis UK</source><source>Springer Link</source><creator>Nguyen, Quoc-Bao D ; Starling, Caroline T ; Hebert, Adelaide A</creator><creatorcontrib>Nguyen, Quoc-Bao D ; Starling, Caroline T ; Hebert, Adelaide A</creatorcontrib><description>Tumor necrosis factor alpha (TNF) inhibitors have had a significant impact in medicine since the approval of the first drug of its class by the US FDA in 1998. New clinical data and indications have emerged for TNF inhibitors in recent years. Currently, four TNF inhibitors have been approved by the US FDA for dermatology, two of which include US FDA-approved pediatric use. In particular, growing evidence supports the use of etanercept and adalimumab as attractive therapies for pediatric psoriasis. Data for use of etanercept in treating toxic epidermal necrolysis and either etanercept or infliximab for Kawasaki disease is expanding. In addition, there have been clinical reports on the use of TNF inhibitors to treat a variety of other pediatric dermatologic conditions. To help clinicians keep pace with the new data provided by many pediatric dermatology studies involving TNF inhibitors, this review provides an overview of the use of TNF inhibitors in the treatment of pediatric plaque psoriasis, hidradenitis suppurativa, atopic dermatitis, pyoderma gangrenosum, toxic epidermal necrolysis, and Kawasaki disease. For TNF inhibitors with little data in the pediatric population, data on adult use is discussed. Furthermore, the review summarizes available clinical data on efficacy, safety, and tolerability of agents currently available.</description><identifier>ISSN: 1174-5878</identifier><identifier>DOI: 10.1007/s40272-020-00394-3</identifier><language>eng</language><publisher>Springer</publisher><subject>Children ; Diseases ; Drug therapy ; Pediatric research ; Skin diseases ; Tumor necrosis factor inhibitors</subject><ispartof>Paediatric drugs, 2020-06, Vol.22 (3), p.311</ispartof><rights>COPYRIGHT 2020 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Nguyen, Quoc-Bao D</creatorcontrib><creatorcontrib>Starling, Caroline T</creatorcontrib><creatorcontrib>Hebert, Adelaide A</creatorcontrib><title>The Use of TNF[alpha] Inhibitors in Treating Pediatric Skin Disorders</title><title>Paediatric drugs</title><description>Tumor necrosis factor alpha (TNF) inhibitors have had a significant impact in medicine since the approval of the first drug of its class by the US FDA in 1998. New clinical data and indications have emerged for TNF inhibitors in recent years. Currently, four TNF inhibitors have been approved by the US FDA for dermatology, two of which include US FDA-approved pediatric use. In particular, growing evidence supports the use of etanercept and adalimumab as attractive therapies for pediatric psoriasis. Data for use of etanercept in treating toxic epidermal necrolysis and either etanercept or infliximab for Kawasaki disease is expanding. In addition, there have been clinical reports on the use of TNF inhibitors to treat a variety of other pediatric dermatologic conditions. To help clinicians keep pace with the new data provided by many pediatric dermatology studies involving TNF inhibitors, this review provides an overview of the use of TNF inhibitors in the treatment of pediatric plaque psoriasis, hidradenitis suppurativa, atopic dermatitis, pyoderma gangrenosum, toxic epidermal necrolysis, and Kawasaki disease. For TNF inhibitors with little data in the pediatric population, data on adult use is discussed. Furthermore, the review summarizes available clinical data on efficacy, safety, and tolerability of agents currently available.</description><subject>Children</subject><subject>Diseases</subject><subject>Drug therapy</subject><subject>Pediatric research</subject><subject>Skin diseases</subject><subject>Tumor necrosis factor inhibitors</subject><issn>1174-5878</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptjsFLwzAYxXNQcE7_AU8Bz5lfkq9Nehxzc4OhgvUkMtL0SxvdWmn6_2NBDx7kHR48fu_xGLuRsJAA5i4hKKMEKBAAukChz9hMSoMis8ZesMuUPgCk0bmasXXZEn9NxPvAy8fNmzt-te6d77o2VnHsh8Rjx8uB3Bi7hj9THd04RM9fPqf8PqZ-qGlIV-w8uGOi61-fs3KzLldbsX962K2We9Hk0yNUhcYCNSqLgJVXZLXMMxNqpTLpNRRQBGcMBTSATpHO60pWupYgyWWo5-z2Z7ZxRzrELvTj4PwpJn9YGomZtblSE7X4h5pU0yn6vqMQp_xP4RsU4FiZ</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>Nguyen, Quoc-Bao D</creator><creator>Starling, Caroline T</creator><creator>Hebert, Adelaide A</creator><general>Springer</general><scope/></search><sort><creationdate>20200601</creationdate><title>The Use of TNF[alpha] Inhibitors in Treating Pediatric Skin Disorders</title><author>Nguyen, Quoc-Bao D ; Starling, Caroline T ; Hebert, Adelaide A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g672-42934943428404bc2e831657fd2251c30909fa77ef4704a2e36db1b3d101ea543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Children</topic><topic>Diseases</topic><topic>Drug therapy</topic><topic>Pediatric research</topic><topic>Skin diseases</topic><topic>Tumor necrosis factor inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nguyen, Quoc-Bao D</creatorcontrib><creatorcontrib>Starling, Caroline T</creatorcontrib><creatorcontrib>Hebert, Adelaide A</creatorcontrib><jtitle>Paediatric drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nguyen, Quoc-Bao D</au><au>Starling, Caroline T</au><au>Hebert, Adelaide A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Use of TNF[alpha] Inhibitors in Treating Pediatric Skin Disorders</atitle><jtitle>Paediatric drugs</jtitle><date>2020-06-01</date><risdate>2020</risdate><volume>22</volume><issue>3</issue><spage>311</spage><pages>311-</pages><issn>1174-5878</issn><abstract>Tumor necrosis factor alpha (TNF) inhibitors have had a significant impact in medicine since the approval of the first drug of its class by the US FDA in 1998. New clinical data and indications have emerged for TNF inhibitors in recent years. Currently, four TNF inhibitors have been approved by the US FDA for dermatology, two of which include US FDA-approved pediatric use. In particular, growing evidence supports the use of etanercept and adalimumab as attractive therapies for pediatric psoriasis. Data for use of etanercept in treating toxic epidermal necrolysis and either etanercept or infliximab for Kawasaki disease is expanding. In addition, there have been clinical reports on the use of TNF inhibitors to treat a variety of other pediatric dermatologic conditions. To help clinicians keep pace with the new data provided by many pediatric dermatology studies involving TNF inhibitors, this review provides an overview of the use of TNF inhibitors in the treatment of pediatric plaque psoriasis, hidradenitis suppurativa, atopic dermatitis, pyoderma gangrenosum, toxic epidermal necrolysis, and Kawasaki disease. For TNF inhibitors with little data in the pediatric population, data on adult use is discussed. Furthermore, the review summarizes available clinical data on efficacy, safety, and tolerability of agents currently available.</abstract><pub>Springer</pub><doi>10.1007/s40272-020-00394-3</doi></addata></record>
fulltext fulltext
identifier ISSN: 1174-5878
ispartof Paediatric drugs, 2020-06, Vol.22 (3), p.311
issn 1174-5878
language eng
recordid cdi_gale_infotracmisc_A714588622
source Nexis UK; Springer Link
subjects Children
Diseases
Drug therapy
Pediatric research
Skin diseases
Tumor necrosis factor inhibitors
title The Use of TNF[alpha] Inhibitors in Treating Pediatric Skin Disorders
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T18%3A12%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Use%20of%20TNF%5Balpha%5D%20Inhibitors%20in%20Treating%20Pediatric%20Skin%20Disorders&rft.jtitle=Paediatric%20drugs&rft.au=Nguyen,%20Quoc-Bao%20D&rft.date=2020-06-01&rft.volume=22&rft.issue=3&rft.spage=311&rft.pages=311-&rft.issn=1174-5878&rft_id=info:doi/10.1007/s40272-020-00394-3&rft_dat=%3Cgale%3EA714588622%3C/gale%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-g672-42934943428404bc2e831657fd2251c30909fa77ef4704a2e36db1b3d101ea543%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A714588622&rfr_iscdi=true